Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07729839
PHASE1

Safety, Tolerability, and Pharmacokinetic Evaluation of ADB116 for Injection

Sponsor: Jiangsu Aidea Pharmaceutical Group Co., Ltd.

View on ClinicalTrials.gov

Summary

A Phase I Study of ADB116 for Injection in Healthy Chinese Adults. This study aims as follows: Primary Objective: • To evaluate the safety and tolerability of a single intravenous bolus dose of ADB116 for injection in healthy Chinese adults. Secondary Objective: • To evaluate the pharmacokinetic (PK) profile of a single intravenous bolus dose of ADB116 for injection.

Official title: Study of Safety, Tolerability, and Pharmacokinetics of ADB116 for Injection in Healthy Chinese Adults: A Single-Center, Randomized, Double-Blind, Placebo-Controlled, Single-Ascending-Dose Phase I Clinical Trial

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

26

Start Date

2026-05-31

Completion Date

2026-08-30

Last Updated

2026-07-28

Healthy Volunteers

Yes

Interventions

DRUG

ADB116 for Injection

ADB116 for Injection, single intravenous bolus injection

DRUG

Placebo for ADB116 for Injection

Matching placebo, single intravenous bolus injection

Locations (1)

NanFang Hospital of Southern Medical University

Guangzhou, Guangdong, China